Get the Stockscreener App
5.81
1.93%
0.11
After Hours:
5.83
0.02
+0.34%
Amylyx Pharmaceuticals Inc stock is traded at $5.81, with a volume of 770.03K.
It is up +1.93% in the last 24 hours and up +86.22% over the past month.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder.
See More
Previous Close:
$5.70
Open:
$5.67
24h Volume:
770.03K
Relative Volume:
0.60
Market Cap:
$395.56M
Revenue:
$380.79M
Net Income/Loss:
$49.27M
P/E Ratio:
-4.6855
EPS:
-1.24
Net Cash Flow:
$10.68M
1W Performance:
+14.60%
1M Performance:
+86.22%
6M Performance:
+186.21%
1Y Performance:
-68.48%
1-Day Range:
$5.53
$5.83
1-Week Range:
$5.06
$5.83
52-Week Range:
$1.575
$19.95
Amylyx Pharmaceuticals Inc Stock (AMLX) Company Profile
Name
Amylyx Pharmaceuticals Inc
Sector
Industry
Phone
617-683-0917
Address
43 THORNDIKE STREET, CAMBRIDGE
Amylyx Pharmaceuticals Inc Stock (AMLX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-03-24 | Initiated | Robert W. Baird | Outperform |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Jul-24-23 | Upgrade | Goldman | Neutral → Buy |
| Mar-31-23 | Initiated | Mizuho | Buy |
| Jan-05-23 | Initiated | BofA Securities | Buy |
| May-25-22 | Initiated | Citigroup | Buy |
| Apr-01-22 | Downgrade | Goldman | Buy → Neutral |
View All
Amylyx Pharmaceuticals Inc Stock (AMLX) Latest News
Amylyx Pharmaceuticals (AMLX) to Release Earnings on Thursday - MarketBeat
Vanguard Group Inc's Strategic Reduction in Amylyx Pharmaceutica - GuruFocus.com
There's No Escaping Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) Muted Revenues Despite A 81% Share Price Rise - Simply Wall St
Amylyx Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 7, 2024 - StockTitan
abrdn plc Buys 1,853,995 Shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - MarketBeat
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
Levi & Korsinsky Reminds Amylyx Investors of the Pending Class A - GuruFocus.com
Short Interest in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Declines By 21.1% - MarketBeat
Perceptive Advisors LLC's Strategic Acquisition in Amylyx Pharmaceuticals Inc - Yahoo Finance
Amylyx upgraded to buy by BofA on hypoglycemia drug potential - MSN
BofA upgrades Amylyx stock to Buy rating By Investing.com - Investing.com Australia
BofA upgrades Amylyx stock to Buy rating - Investing.com
Amylyx Pharmaceuticals (NASDAQ:AMLX) Upgraded to Buy by Bank of America - MarketBeat
Levi & Korsinsky Announces the Filing of a Securities Class Acti - GuruFocus.com
Amylyx Pharmaceuticals reports results from pancreatic disease treatment trial - MSN
Amylyx Pharmaceuticals (AMLX): Leading Nano Cap in Neurodegenerative Disease Treatments - Insider Monkey
Why Amylyx Pharmaceuticals Stock Was So Healthy This Week - MSN
Amylyx shares reiterate Buy rating on trial data - Investing.com
Amylyx shares reiterate Buy rating on trial data By Investing.com - Investing.com UK
Amylyx Pharmaceuticals (NASDAQ:AMLX) Receives "Buy" Rating from HC Wainwright - MarketBeat
H.C. Wainwright maintains Buy rating on Amylyx shares on trial data - Investing.com
H.C. Wainwright maintains Buy rating on Amylyx shares on trial data By Investing.com - Investing.com UK
Amylyx’s AMX0035 shows promise in Phase II Wolfram syndrome trial - Clinical Trials Arena
PTC rebuffed again by EMA; Novartis licenses China-based biotech’s cancer drug - Yahoo Finance
Leerink maintains Market Perform rating on Amylyx stock on new data - Investing.com
Leerink maintains Market Perform rating on Amylyx stock on new data By Investing.com - Investing.com South Africa
Amylyx reports positive trial results for Wolfram syndrome treatment - Investing.com India
Amylyx reports positive trial results for Wolfram syndrome treatment By Investing.com - Investing.com South Africa
Amylyx Pharmaceuticals Announces Positive Topline Results from Phase 2 HELIOS Clinical Trial Demonstrating Sustained Improvements with AMX0035 in People Living with Wolfram Syndrome - Business Wire
Amylyx Pharmaceuticals to Host Virtual Webcast to Discuss Topline Results from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndrome on October 17, 2024 - BioSpace
Amyotrophic Lateral Sclerosis Market 2034 | Mitsubishi Tanabe - openPR
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Shares Sold by Millennium Management LLC - MarketBeat
Deutsche Bank Initiates Coverage of Amylyx Pharmaceuticals (AMLX) with Buy Recommendation - MSN
Brokerages Set Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Target Price at $17.60 - MarketBeat
American Century Companies Inc. Reduces Stake in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - MarketBeat
AQR Capital Management LLC Acquires 3,224,454 Shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - MarketBeat
Kuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law Firm - Marketscreener.com
Amylyx Pharmaceuticals executive sells over $27k in company stock - Investing.com India
Amylyx Pharmaceuticals executive sells over $27k in company stock By Investing.com - Investing.com Canada
Amylyx Pharmaceuticals executive sells over $36k in company stock - Investing.com
Amylyx Pharmaceuticals executive sells over $36k in company stock By Investing.com - Investing.com Australia
Insider Selling: Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Insider Sells 11,442 Shares of Stock - MarketBeat
Amylyx Pharmaceuticals CEO sells over $59k in stock By Investing.com - Investing.com South Africa
Amylyx Co-CEO sells over $59,000 in company stock By Investing.com - Investing.com South Africa
Amylyx Pharmaceuticals CEO sells over $59k in stock - Investing.com
Amylyx Co-CEO sells over $59,000 in company stock - Investing.com
Amylyx Pharmaceuticals Navigates Shift to Smaller Reporting Status: Impacts on Investor Relations and Stock Volatility - TipRanks
Amyotrophic Lateral Sclerosis Treatment Market is Booming with - openPR
Almitas Capital LLC Makes New Investment in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - Defense World
Amylyx Pharmaceuticals Inc Stock (AMLX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.02%
0.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):